The Clinical Pharmacology and Analyfical Chemistry (CPAC) Core contains clinical pharmacology expertise with a CLIA-certified laboratory to support clinical and preclinical HIV/AIDS research among CFAR invesfigators at UNC, FHl, and RTI. Since the CPAC Core is the only one of its kind within the CFAR system, it also supports a growing number of invesfigators in other CFARs across the country. The CPAC Core consists of experienced scientists who provide a high level of expertise in trial design, development and validation of analytical methods in complex biological matrices to accurately quantify drug exposure, and interpretation of preclinical and clinical pharmacology data. The CPAC Core also provides leadership in HIV prevention strategies, women's health issues, and international pharmacology, and trains domestic and international investigators in pharmacologic and analytic methods.

Public Health Relevance

A major feature of controlling the HIV epidemic is the complex interplay between drug exposure and response in treatment, prevention, and cure. This is evidenced in the extensive preclinical and early clinical dose-response investigations during drug development. Optimizing effective therapy in any of these areas of the epidemic requires extensive knowledge of exposure targets and pharmacokinefics in multiple body compartments to chose the best doses, dosing frequencies, and drug combinations for efficacy. The CPAC Core provides the necessary resources for CFAR users to optimize their preclinical and clinical research approach.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI050410-17
Application #
8708740
Study Section
Special Emphasis Panel (ZAI1-ELB-A)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
17
Fiscal Year
2014
Total Cost
$292,130
Indirect Cost
$94,464
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Cole, Stephen R; Edwards, Jessie K; Westreich, Daniel et al. (2018) Estimating multiple time-fixed treatment effects using a semi-Bayes semiparametric marginal structural Cox proportional hazards regression model. Biom J 60:100-114
Dhungel, Bal Mukunda; Montgomery, Nathan D; Painschab, Matthew S et al. (2018) 'Discovering' primary effusion lymphoma in Malawi. AIDS 32:2264-2266
Ewing, Alexander C; Ellington, Sascha R; Wiener, Jeffrey B et al. (2018) Predictors of Perinatal HIV Transmission Among Women Without Prior Antiretroviral Therapy in a Resource-Limited Setting: The BAN Study. Pediatr Infect Dis J :
Davy-Mendez, Thibaut; Napravnik, Sonia; Zakharova, Oksana et al. (2018) Acute HIV Infection and CD4/CD8 Ratio Normalization After Antiretroviral Therapy Initiation. J Acquir Immune Defic Syndr 79:510-518
Rosenberg, Nora E; Bhushan, Nivedita L; Vansia, Dhrutika et al. (2018) Comparing Youth-Friendly Health Services to the Standard of Care Through ""Girl Power-Malawi"": A Quasi-Experimental Cohort Study. J Acquir Immune Defic Syndr 79:458-466
Pence, Brian W; Bengtson, Angela M; Boswell, Stephen et al. (2018) Who Will Show? Predicting Missed Visits Among Patients in Routine HIV Primary Care in the United States. AIDS Behav :
DiPrete, Bethany L; Pence, Brian W; Bengtson, Angela M et al. (2018) The Depression Treatment Cascade: Disparities by Alcohol Use, Drug Use, and Panic Symptoms Among Patients in Routine HIV Care in the United States. AIDS Behav :
Ascher, Simon B; Scherzer, Rebecca; Estrella, Michelle M et al. (2018) Association of Urinary Biomarkers of Kidney Injury with Estimated GFR Decline in HIV-Infected Individuals following Tenofovir Disoproxil Fumarate Initiation. Clin J Am Soc Nephrol 13:1321-1329
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Tucker, Joseph D; Fenton, Kevin A (2018) Innovation challenge contests to enhance HIV responses. Lancet HIV 5:e113-e115

Showing the most recent 10 out of 1688 publications